Presentation Details:
Objectives:
- Explore the evidence behind and utility of subcutaneous extended release buprenorphine in the management of OUD.
- Review different "microdosing" strategies of induction onto sublingual buprenorphine for patients transitioning from long-acting opioids or with prolonged exposure to fentanyl.
- Discuss practical tips on how to incorporate these strategies into an Office Based Opioid Treatment program.
Presentation Transcript: